Huadong Pharmaceutical Co., Ltd. announced on June 30 that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. received a notice from the US Food and Drug Administration that the clinical trial application for injectable HDM2012 was approved by the US FDA and can conduct phase I clinical trials in the US. The indication is advanced solid tumors.

Zhitongcaijing · 06/30 13:01
Huadong Pharmaceutical Co., Ltd. announced on June 30 that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. received a notice from the US Food and Drug Administration that the clinical trial application for injectable HDM2012 was approved by the US FDA and can conduct phase I clinical trials in the US. The indication is advanced solid tumors.